company background image
OPRX

OptimizeRx NasdaqCM:OPRX Stock Report

Last Price

US$28.96

Market Cap

US$525.7m

7D

6.2%

1Y

-53.2%

Updated

29 Jun, 2022

Data

Company Financials +
OPRX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

OPRX Stock Overview

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients.

OptimizeRx Competitors

Price History & Performance

Summary of all time highs, changes and price drops for OptimizeRx
Historical stock prices
Current Share PriceUS$28.96
52 Week HighUS$99.18
52 Week LowUS$21.33
Beta0.91
1 Month Change10.20%
3 Month Change-23.20%
1 Year Change-53.22%
3 Year Change78.66%
5 Year Change837.21%
Change since IPO-88.64%

Recent News & Updates

Jun 27

OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability

Large and growing TAM with industry tailwinds like digitalization supporting growth in demand for OptimizeRx's solutions. Highly scalable operating model with more than sufficient network capacity to facilitate growth in the near term. OptimizeRx has a strong network of large customers that provides a differentiating factor and competitive advantage to compete against other competitors in the space. The company has a solid balance sheet and has been growing revenue at a rapid pace, setting the stage for near term inflection in profitability. I initiate OptimizeRx with a price target of $48.50, implying 74% upside from current levels.

Shareholder Returns

OPRXUS Healthcare ServicesUS Market
7D6.2%2.8%1.6%
1Y-53.2%-39.8%-20.8%

Return vs Industry: OPRX underperformed the US Healthcare Services industry which returned -40% over the past year.

Return vs Market: OPRX underperformed the US Market which returned -20.4% over the past year.

Price Volatility

Is OPRX's price volatile compared to industry and market?
OPRX volatility
OPRX Average Weekly Movement10.0%
Healthcare Services Industry Average Movement13.1%
Market Average Movement8.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: OPRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: OPRX's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200697Will Febbohttps://www.optimizerx.com

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company’s products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages. It also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products.

OptimizeRx Fundamentals Summary

How do OptimizeRx's earnings and revenue compare to its market cap?
OPRX fundamental statistics
Market CapUS$525.69m
Earnings (TTM)-US$2.75m
Revenue (TTM)US$63.79m

8.2x

P/S Ratio

-191.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OPRX income statement (TTM)
RevenueUS$63.79m
Cost of RevenueUS$26.18m
Gross ProfitUS$37.62m
Other ExpensesUS$40.36m
Earnings-US$2.75m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.15
Gross Margin58.96%
Net Profit Margin-4.30%
Debt/Equity Ratio0%

How did OPRX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is OPRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OPRX?

Other financial metrics that can be useful for relative valuation.

OPRX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6.9x
Enterprise Value/EBITDA609.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does OPRX's PS Ratio compare to its peers?

OPRX PS Ratio vs Peers
The above table shows the PS ratio for OPRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average2.1x
HCAT Health Catalyst
3.3x16.0%US$841.0m
HSTM HealthStream
2.5x8.5%US$655.1m
CPSI Computer Programs and Systems
1.6x8.0%US$462.0m
BBLN Babylon Holdings
0.8x31.7%US$413.9m
OPRX OptimizeRx
8.2x29.8%US$525.7m

Price-To-Sales vs Peers: OPRX is expensive based on its Price-To-Sales Ratio (8.2x) compared to the peer average (2.1x).


Price to Earnings Ratio vs Industry

How does OPRX's PE Ratio compare vs other companies in the US Healthcare Services Industry?

Price-To-Sales vs Industry: OPRX is expensive based on its Price-To-Sales Ratio (8.2x) compared to the US Healthcare Services industry average (3.3x)


Price to Sales Ratio vs Fair Ratio

What is OPRX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OPRX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.2x
Fair PS Ratio6.6x

Price-To-Sales vs Fair Ratio: OPRX is expensive based on its Price-To-Sales Ratio (8.2x) compared to the estimated Fair Price-To-Sales Ratio (6.6x).


Share Price vs Fair Value

What is the Fair Price of OPRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: OPRX ($28.96) is trading below our estimate of fair value ($171.73)

Significantly Below Fair Value: OPRX is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OPRX's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is OptimizeRx forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


157.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OPRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OPRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OPRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OPRX's revenue (29.8% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: OPRX's revenue (29.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OPRX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has OptimizeRx performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-0.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: OPRX is currently unprofitable.

Growing Profit Margin: OPRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OPRX is unprofitable, and losses have increased over the past 5 years at a rate of 0.4% per year.

Accelerating Growth: Unable to compare OPRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OPRX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (3.7%).


Return on Equity

High ROE: OPRX has a negative Return on Equity (-2.1%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is OptimizeRx's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: OPRX's short term assets ($112.7M) exceed its short term liabilities ($6.9M).

Long Term Liabilities: OPRX's short term assets ($112.7M) exceed its long term liabilities ($212.9K).


Debt to Equity History and Analysis

Debt Level: OPRX is debt free.

Reducing Debt: OPRX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable OPRX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: OPRX is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 12.8% per year.


Discover healthy companies

Dividend

What is OptimizeRx current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate OPRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OPRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OPRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OPRX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as OPRX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Will Febbo (52 yo)

6.33yrs

Tenure

US$14,619,576

Compensation

Mr. William J. Febbo, also known as Will, serves as an Independent Director at Augmedix, Inc. since March 28, 2022. He serves as an Independent Director of Modular Medical, Inc. since January 23, 2020. He...


CEO Compensation Analysis

Compensation vs Market: Will's total compensation ($USD14.62M) is above average for companies of similar size in the US market ($USD2.81M).

Compensation vs Earnings: Will's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: OPRX's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: OPRX's board of directors are considered experienced (5.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5%.


Top Shareholders

Company Information

OptimizeRx Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: OptimizeRx Corporation
  • Ticker: OPRX
  • Exchange: NasdaqCM
  • Founded: 2006
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Implied Market Cap: US$525.692m
  • Shares outstanding: 18.15m
  • Website: https://www.optimizerx.com

Number of Employees


Location

  • OptimizeRx Corporation
  • 400 Water Street
  • Suite 200
  • Rochester
  • Michigan
  • 48307
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/29 00:00
End of Day Share Price2022/06/29 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.